Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
Hiding how much you use or having withdrawal can also signal a larger problem
Hoping to keep up with your kids without feeling out of breath
The strongest data exists for OCD (multiple RCTs showing symptom reduction as adjunct to SSRIs), trichotillomania (hair-pulling disorder), and substance use disorders (particularly cocaine and cannabis dependence)
Doctors who treat obesity say the initiative, Medicare GLP-1 Bridge, could help millions of older adults who, like Kathryn, struggle to pay for the drugs or could not afford to even start taking them but said that questions remain about the federal governments administration of the program